Search Results
Niels Van de Donk | EHA 2018 | Immunotherapy in myeloma: why, when and how?
Niels Van de Donk | ASCO 2018 | What to do when antibodies fail in MM
Niels van de Donk | ESH MM 2018 | Plasma cell leukemia and extramedullary disease
Niels van de Donk, MD, PhD, Discusses MajesTEC-1 Follow-Up Data on Teclistamab in Multiple Myeloma
Immunotherapy in myeloma: current strategies and future perspectives
Niels Van de Donk | EHA 2018 | Immuuntherapie bij myeloom: waarom, wanneer en hoe?
Mechanisms of resistance in multiple myeloma treatments
Perspectives from the Netherlands - Niels van de Donk, MD | MCRT Webcast Jun 26, 2021
Advancements in quadruplet regimens for the treatment of multiple myeloma
Mechanisms of action of CD38 antibodies in myeloma
A novel mechanism of action for daratumumab in myeloma
Sustained MRD for treatment guidance in myeloma
